15 pending office actions • 5 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Takeda Pharmaceutical Company Limited | 10 |
| Keros Therapeutics, Inc. | 2 |
| Fortvita Biologics (Singapore) Pte. Ltd. | 1 |
| Takeda Pharmaceutical Compamy Limited | 1 |
| Protagonist Therapeutics, Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19376374 | Untitled | Fortvita Biologics (Singapore) Pte. Ltd. | ALSOMAIRY, SARAH ABDOALATIF | 1646 | Non-Final OA | |
| 18390137 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Takeda Pharmaceutical Company Limited | CARCANAGUE, DANIEL R | 1621 | Non-Final OA | Dec 20, 2023 |
| 18318218 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | Takeda Pharmaceutical Company Limited | STOICA, ELLY GERALD | 1647 | Non-Final OA | May 16, 2023 |
| 18316151 | POOLING DEVICE FOR SINGLE OR MULTIPLE MEDICAL CONTAINERS | Takeda Pharmaceutical Company Limited | ZIMBOUSKI, ARIANA | 3781 | Final Rejection | May 11, 2023 |
| 18128465 | METHODS OF USING ACTIVIN RECEPTOR TYPE II VARIANTS | Keros Therapeutics, Inc. | LEE, JIA-HAI | 1658 | Non-Final OA | Mar 30, 2023 |
| 18024597 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEIN CONSTRUCTS WITH HUMAN SERUM ALBUMIN DOMAINS | Takeda Pharmaceutical Company Limited | PETERS, ALEC JON | 1641 | Non-Final OA | Mar 03, 2023 |
| 18172433 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | Takeda Pharmaceutical Compamy Limited | MELCHIOR, JAMES RYLAND | 1644 | Non-Final OA | Feb 22, 2023 |
| 18021730 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | Takeda Pharmaceutical Company Limited | CHASE, CAROL ANN | 1646 | Non-Final OA | Feb 16, 2023 |
| 18160407 | LIBRARIES OF GENETIC PACKAGES COMPRISING NOVEL HC CDR1, CDR2, AND CDR3 AND NOVEL LC CDR1, CDR2, AND CDR3 DESIGNS | Takeda Pharmaceutical Company Limited | BOESEN, CHRISTIAN C | 1684 | Non-Final OA | Jan 27, 2023 |
| 18016825 | Conjugated Hepcidin Mimetics | Protagonist Therapeutics, Inc. | HA, JULIE | 1654 | Non-Final OA | Jan 18, 2023 |
| 17916621 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | Takeda Pharmaceutical Company Limited | WEN, SHARON X | 1641 | Non-Final OA | Oct 03, 2022 |
| 17945324 | METHODS OF USING ACTIVIN RECEPTOR TYPE IIA VARIANTS | Keros Therapeutics, Inc. | BORGEEST, CHRISTINA M | 1675 | Final Rejection | Sep 15, 2022 |
| 17745770 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | Takeda Pharmaceutical Company Limited | KOLKER, DANIEL E | 1645 | Final Rejection | May 16, 2022 |
| 17672748 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | Takeda Pharmaceutical Company Limited | OGUNBIYI, OLUWATOSIN A | 1645 | Non-Final OA | Feb 16, 2022 |
| 17491813 | EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS | Takeda Pharmaceutical Company Limited | PETRASH, HILARY ANN | 1644 | Non-Final OA | Oct 01, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial